Arrowhead Pharmaceuticals (ARWR) Retained Earnings (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Retained Earnings data on file, last reported at -$1.7 billion in Q1 2026.

• Quarterly Retained Earnings fell 39486.67% year-over-year to -$1.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.7 billion (down 39486.67% YoY) and the FY2025 annual result came in at $6.4 million, up 100.4% from the prior year.
• Retained Earnings retreated to -$1.7 billion in Q1 2026, from -$1.6 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $6.4 million in Q3 2025 to a low of -$1.8 billion in Q4 2024.
• A 5-year average of -$671.6 million and a median of -$1.3 million in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings slumped 754333.82% — and 2025, when it jumped 100.4%.
• Tracing ARWR's Retained Earnings over 5 years: stood at -$258000.0 in 2022, then slumped by 386.43% to -$1.3 million in 2023, then tumbled by 143215.38% to -$1.8 billion in 2024, then increased by 11.25% to -$1.6 billion in 2025, then dropped by 8.31% to -$1.7 billion in 2026.
• The last three Retained Earnings figures came in at -$1.7 billion (Q1 2026), -$1.6 billion (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.